Pathology, Inc. and CombiMatrix Expand Partnership in Prenatal Testing Market

Pathology, Inc. and CombiMatrix Expand Partnership in Prenatal Testing Market

CombiMatrix Becomes Exclusive Provider of Testing for Products of Conception

IRVINE, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer, today announced that it has
been selected by Pathology, Inc. to be its exclusive provider of chromosomal
microarray tests for the Products of Conception (POC) testing market
throughout the United States. POC testing, also referred to as miscarriage
testing, is a subset of the overall prenatal testing market.

The announcement is an expansion of the previous strategic partnership between
the two companies announced in November 2012 that gave Pathology, Inc. the
right to market and distribute microarray tests on behalf of CombiMatrix in
the states of California and Nevada, as well as the St. Louis and Chicago
metropolitan areas.

"The partnership has been very beneficial for both parties to date, and I
believe it will benefit our physician partners and their patients to extend
the working relationship we have established with CombiMatrix," said Vicki
DiFrancesco, President and CEO of Pathology, Inc., a full service, independent
Women's Health laboratory based in Torrance, California. "The POC market is an
important segment of women's health for Pathology, Inc. and we are pleased to
be working with an advanced laboratory like CombiMatrix that specializes in
microarray testing. We believe this market is going to continue to expand as
our physician customers and their patients realize the importance of
microarray testing in helping to identify the causes of miscarriages and how
that information may assist in future pregnancies."

CombiMatrix President and Chief Executive Officer Mark McDonough said, "The
expansion of this partnership underscores the rapidly expanding importance of
microarray testing and the value our team brings to Pathology, Inc. in terms
of operational and analytical support.Pathology, Inc. is one of the leading
women's health labs in the nation and we are very pleased to be recognized by
these experts as a valuable partner.

"Working closely with Pathology, Inc. allows us to extend our customer base of
OB/GYNs and provides us with additional marketing and distribution support.
Our relationship will only become more important as the national healthcare
market learns about the benefits of chromosomal microarray testing," continued
McDonough.

About Pathology, Inc.

Pathology, Inc. is a full-service provider of anatomic and clinical pathology
testing services, with a 30-year foundation in the Women's Health market. With
expertise in molecular and digital pathology, the Company has built a solid
reputation for quality and customer service with clients that include OB/Gyns,
dermatologists, urologists, gastroenterologists, and family practitioners, as
well as surgicenters, endoscopy centers, hospitals, and independent
laboratories. Pathology, Inc. is located at three separate facilities; its
Torrance headquarters, a second facility in Templeton, CA (Central Coast
Clinical Laboratories) and a third laboratory in Wood Dale, IL. All three
facilities are CLIA certified and CAP accredited. Pathology, Inc.'s
pathologists, through its association with Affiliated Pathologists Medical
Group (APMG), are board certified and have a variety of multi-specialty
interests and expertise, as well as extensive cumulative experience in
outpatient pathology. Pathology, Inc. has provided pathology services to
physician offices and pathologists for over 25 years.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of abnormalities of genes at
the DNA level beyond what can be identified through traditional
technologies.The Company performs genetic testing utilizing microarray, FISH,
PCR and G-Band chromosome analyses. Additional information about CombiMatrix
is available at www.combimatrix.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not limited to,
statements regarding projected results of operations and management's future
business, operational and strategic plans, momentum of our pre-natal and
pediatric businesses, test menu expansion, services and reports development
and attracting greater prenatal genetic screening business.These
forward-looking statements are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in any
forward-looking statement.The risks and uncertainties referred to above
include, but are not limited to: our ability to gain more market share,
capitalize on markets and grow shareholder value; our ability to successfully
expand the base of our customers and strategic partners, add to the menu of
our diagnostic tests in both of our primary markets, develop and introduce new
tests and related reports, optimize the reimbursements received for our
testing services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to successfully
accelerate sales, steadily increase the size of our customer rosters in both
developmental medicine and oncology; lack of growth in the developmental
markets; our ability to attract and retain a qualified sales force; rapid
technological change in our markets; changes in demand for our future
products; the ability of microarray technology to become the standard of care;
legislative, regulatory and competitive developments; general economic
conditions; and various other factors.Further information on potential
factors that could affect our financial results is included in our Annual
Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with
the Securities and Exchange Commission.We undertake no obligation to revise
or update publicly any forward-looking statements for any reason, except as
required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
 
Press spacebar to pause and continue. Press esc to stop.